Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

David Tougeron, MD, PhD

Pembrolizumab Plus Bevacizumab/CAPOX Yields Responses in pMMR/MSS mCRC With High TILs

July 1st 2024

Pembrolizumab plus bevacizumab and CAPOX produced responses in pMMR/MSS metastatic colorectal cancer with high immune infiltrate.

Markus Moehler, MD, PhD

TAP Score and CPS May Be Viable for PD-L1 Expression Measurement in Advanced Gastric Cancers

July 1st 2024

Concordance between TAP score and CPS at matched thresholds indicate their viability for assessing PD-L1 expression in advanced gastric cancers.

Kristen K. Ciombor, MD, MSCI

Nivolumab/Ipilimumab/Radiation Combo Produces Responses in Locally Advanced Rectal Cancer

July 1st 2024

The EA2201 trial evaluated nivolumab, ipilimumab, and short-course radiation therapy in patients with locally advanced rectal cancer.

Mehraneh D. Jafari, MD

Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status

July 1st 2024

Botensilimab and balstilimab demonstrated pathological responses across subsets of patients with resectable colon cancer.

Dr Maximiliano Gelli, Gustave Roussy

TRANSMET Regimen Proves Safe, Feasible for Definitively Unresectable CRC Liver Metastasis

June 28th 2024

Liver transplantation plus chemotherapy demonstrated no concerning safety signals or long-term deterioration in QOL in patients with definitively unresectable CRC liver metastasis.

Gastric cancer | Image Credit: © Rasi - stock.adobe.com

Switch Ramucirumab/Paclitaxel Maintenance Yields Favorable Outcomes in HER2– Gastric Cancer

June 28th 2024

Switch ramucirumab/paclitaxel maintenance improved PFS and OS outcomes vs chemotherapy continuation in HER2-negative gastric or GEJ cancer.

Michel P. Ducreux, MD, PhD

TAS-102 Followed By Regorafenib Identified As Optimal Treatment Sequence in Pretreated mCRC

June 28th 2024

TAS-102 followed by regorafenib is an optimal sequence vs regorafenib followed by TAS-102 in select patients with metastatic colorectal cancer.

Sara Lonardi, MD

Frontline Nivolumab Plus Ipilimumab Reduces Symptomatic Burden in MSI-H/dMMR mCRC

June 28th 2024

HRQOL data from the CheckMate 8HW trial may support the use of nivolumab and ipilimumab as first-line treatment for patients with MSI-H or dMMR metastatic colorectal cancer.

Elisa Fontana, MD, PhD

Lunresertib Plus FOLFIRI Shows Safety, Elicits Responses in CCNE1+ or FBXW7+ Advanced GI Tumors

June 27th 2024

Lunresertib plus FOLFIRI was safe and produced responses in advanced gastrointestinal tumors harboring CCNE1 amplifications or FBXW7 alterations.

Jeremy Abramson, MD, of Massachusetts General Hospital

Liso-cel Shows Improved EFS, PFS, and Durable Responses in Second-line LBCL at 3 Years

June 27th 2024

Liso-cel continued to show improved disease control and EFS and PFS vs SOC in the second-line treatment of patients with large B-cell lymphoma.

Simron Singh, MD, MPH

Lutetium Lu 177 Dotatate Maintains PFS, ORR Benefits Across Subgroups in SSTR+ GEP-NETs

June 26th 2024

Lutetium Lu 177 dotatate with octreotide led to a clinical benefit in PFS and ORR regardless of tumor grade or primary origin in advanced grade 2 and grade 3 GEP-NETs.

Mansoor Raza Mirza, MD

Dostarlimab/Chemo/Niraparib Generates PFS Benefit in Primary/Recurrent Endometrial Cancer

June 25th 2024

Dostarlimab/chemotherapy/niraparib elicited favorable PFS outcomes across several subgroups in primary advanced or recurrent endometrial cancer.

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, a consultant medical oncologist and clinical senior lecturer in the Department of Oncology at the University College-London Cancer Institute in England

Rucaparib Maintenance Elicits Continued PFS Benefit Across Newly Diagnosed Ovarian Cancer Subgroups

June 24th 2024

First-line rucaparib maintenance therapy maintained a PFS benefit vs placebo at 4 years of follow-up in newly diagnosed advanced ovarian cancer.

Sandro Pignata, MD, PhD, of IRCCS National Cancer Institute “Fondazione G. Pascale”

Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer

June 21st 2024

First-line lenvatinib plus pembrolizumab demonstrated antitumor activity across various histologic subtypes in advanced or recurrent endometrial cancer.

Els Van Nieuwenhuysen, MD, of UZ Leuven

Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancer

June 21st 2024

Durvalumab plus chemotherapy, followed by durvalumab maintenance with or without olaparib, improved responses in advanced endometrial cancer.

Barbara Jane O’Brien, MD, of The University of Texas MD Anderson Cancer Center

Tucatinib-Based Regimen Improves Target Deficits, QOL in HER2+ Breast Cancer With Leptomeningeal Metastasis

June 21st 2024

Patients with leptomeningeal metastasis from HER2-positive breast cancer experienced clinical benefit with tucatinib plus trastuzumab and capecitabine.

Susana Banerjee, MBBS, MA, PhD, FRCP, consultant medical oncologist, research lead, Gynaecology Unit, The Royal Marsden NHS Foundation Trust

Mirvetuximab Soravtansine Elicits Benefits in Ovarian Cancer Regardless of Dose Modifications

June 21st 2024

Mirvetuximab soravtansine generated PFS, OS, and ORR improvements in patients with ovarian cancer who required dose modifications in the MIRASOL trial.

Fabian Trillsch, MD

Durvalumab Combo Before Olaparib-Based Maintenance Sustains PFS Benefit in BRCA-Unmutated Ovarian Cancer

June 20th 2024

Durvalumab/chemotherapy/bevacizumab, then durvalumab/bevacizumab/olaparib maintenance, sustained a PFS benefit in BRCA-unmutated advanced ovarian cancer.

Isabelle Ray-Coquard, MD, PhD, of Centre Leon Berard

ROCSAN Study Step I Misses 16-Week ORR End Point in Endometrial or Ovarian Carcinosarcoma

June 20th 2024

ROCSAN step 1 did not meet its primary end point of 16-week response rate with niraparib or dostarlimab/niraparib in endometrial/ovarian carcinosarcoma.

Alexandra Leary, MD, PhD

Vibostolimab Plus Pembrolizumab Fails to Boost Efficacy in Pretreated PD-L1+ Cervical Cancer

June 20th 2024

Vibostolimab plus pembrolizumab was not superior to pembrolizumab monotherapy in pretreated PD-L1–positive advanced cervical cancer.

Consuelo Bertossi, MD, of University Hospital Ulm in Germany

TP53 Mutations Are Associated With Unfavorable Prognosis in CLL

June 18th 2024

TP53 mutations have an adverse prognostic role in CLL, regardless of 17p deletion status, in the context of chemoimmunotherapy and targeted agents.

Xavier Leleu, MD, MSc, PhD, head, Myeloma Clinic, Poitiers University Hospital

Ide-Cel Generates Durable Responses in Functionally High-Risk Myeloma

June 18th 2024

Ide-cel induced durable responses and had a favorable risk-benefit profile in patients with functionally high-risk multiple myeloma.

Michael Wang, MD, of The University of Texas MD Anderson Cancer Center

Frontline Acalabrutinib/BR Regimen Significantly Improves PFS in Mantle Cell Lymphoma

June 17th 2024

Frontline treatment with acalabrutinib and bendamustine/rituximab (BR) improved PFS over BR alone in older patients with mantle cell lymphoma.

Stephen Opat, of Monash Health

Sonrotoclax Plus Zanubrutinib Is Safe, Efficacious in Relapsed/Refractory CLL/SLL

June 17th 2024

The combination of sonrotoclax and zanubrutinib had a tolerable safety profile and led to durable responses in relapsed/refractory CLL/SLL.

Suzanne Lentzsch, MD, PhD, professor, clinical medicine, director, Multiple Myeloma and Amyloidosis Program, College of Physicians and Surgeons, Columbia University Medical Center and NewYork-Presbyterian Hospital

Linvoseltamab Elicits Deep, Durable Responses in R/R Multiple Myeloma

June 17th 2024

Linvoseltamab induced durable responses in patients with relapsed or refractory multiple myeloma, including those with high-risk features.

Ruben A. Mesa, MD, FACP, of Atrium Health Levine Cancer Institute

Prospective Analysis Highlights Patterns of Progression to Myelofibrosis Following Essential Thrombocythemia Diagnosis

June 17th 2024

Patients with essential thrombocythemia who progressed to myelofibrosis had longer duration of disease, higher white blood cell counts, and lower hemoglobin levels at enrollment.

Jing-Zhou Hou, MD, PhD, of UPMC Hillman Cancer Center

Acalabrutinib and Zanubrutinib Both Best Ibrutinib in Real-World Safety and Efficacy CLL/SLL Outcomes

June 17th 2024

Acalabrutinib and zanubrutinib monotherapy displayed better real-world safety and efficacy in chronic lymphocytic leukemia and small lymphocytic lymphoma compared with ibrutinib.

William Wierda, MD, PhD

Lower Tumor Burden Associated With Improved ORR With Liso-Cel in R/R CLL/SLL

June 17th 2024

Lower disease burden improves response to liso-cel treatment in CLL/SLL, reports TRANSCEND CLL 004 trial.

Sujith Samarasinghe, MD

Dr Samarasinghe on the Feasibility of First-Line Blinatumomab in Down Syndrome B-ALL

June 16th 2024

Sujith Samarasinghe, MD, discusses key results from the phase 2 ALLTOGETHER 1 DS trial in Down Syndrome B-cell acute lymphoblastic leukemia.

Suzanne Trudel, MSc, MD

Dr Trudel on Results From the DREAMM-7 Trial of BVd in R/R Multiple Myeloma

June 16th 2024

Suzanne Trudel, MSc, MD, discusses key results and subgroup analyses from the phase 3 DREAMM-7 trial of BVd in relapsed/refractory multiple myeloma.